RxDoctor Payments Data

Diosdado Irlandez, MD

Cardiovascular Disease · Marietta, GANPI 1386613339

Payments from drug & device makers

$3,559in general payments, 2019–2025

Across 154 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$862
  • W. L. Gore & Associates, Inc.$265
  • Medtronic$246
  • Boehringer Ingelheim$218
  • Amarin Pharma, Inc.$196
  • E.r. Squibb & Sons, L.L.C.$195
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,547100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,559 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$172,246
Medicare patients
1,473
Services billed
4,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$294,624
XareltoRivaroxaban33$50,694
EntrestoSacubitril/Valsartan41$48,011
JardianceEmpagliflozin14$19,419
BrilintaTicagrelor14$12,283
Ranolazine ErRanolazine51$5,729
Atorvastatin Calcium428$3,380
Verapamil Er PmVerapamil Hcl11$3,106
Carvedilol338$2,479
Metoprolol Succinate205$2,327
Ezetimibe70$1,961
Rosuvastatin Calcium141$1,733
Amiodarone Hcl14$1,544
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$1,495
Losartan Potassium156$1,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$294,624239 claims
Johnson & JohnsonXarelto$190$50,69433 claims
NovartisEntresto$862$48,01141 claims
Boehringer IngelheimJardiance$218$19,41914 claims
AstraZenecaBrilinta$122$12,28314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →